Association of Cardiovascular Risk Factors and Myocardial Fibrosis With Early Cardiac Dysfunction in Type 1 Diabetes: The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study

Abstract

OBJECTIVEWe investigated the association of cardiovascular risk factors and myocardial fibrosis with early cardiac dysfunction in type 1 diabetes.RESEARCH DESIGN AND METHODSParticipants with type 1 diabetes aged 13–39 years without a known history of cardiovascular disease (CVD) (n = 1,441) were recruited into the Diabetes Control and Complications Trial (1983–1993) and subsequently followed in the Epidemiology of Diabetes Interventions and Complications study (1994 to present). Seven hundred fourteen participants underwent cardiac magnetic resonance (CMR) imaging (2007–2009) with late gadolinium enhancement sequences to assess ischemic and nonischemic scars and tagging sequences to evaluate circumferential strain. CMR-derived T1 mapping also was used to assess interstitial fibrosis. The influence of cardiovascular risk factors and myocardial scar on circumferential strain was assessed using linear regression.RESULTSCircumferential dysfunction was consistently associated with older age, male sex, smoking history, obesity, higher blood pressure, lower HDL cholesterol, and higher mean HbA1c. Participants with nonischemic scars (n = 16) had the worst circumferential function compared with those without scars (β ± SE 1.32 ± 0.60; P = 0.03). In sex-adjusted models, the correlation between T1 times and circumferential strain was not significant. In the fully adjusted models, a trend toward circumferential dysfunction in participants with nonischemic scars was found. Left ventricular ejection fraction was not associated with risk factors but was significantly lower if a myocardial scar was present.CONCLUSIONSTraditional CVD risk factors and elevated HbA1c levels are major factors related to early cardiac dysfunction in type 1 diabetes. Nonischemic myocardial scar, possibly as a marker of chronic exposure to known risk factors, may predict early cardiac dysfunction mediated by diffuse myocardial fibrosis as seen in diabetic cardiomyopathy.

SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart

“…Extensive clinical evidence has documented the presence of myocardial fibrosis in patients with diabetes [9, 38]. Many histopathological studies have also confirmed that cardiac fibrosis caused by diabetes occurs independently of hypertension or coronary atherosclerosis [39].…”

Labile glycated haemoglobin and carbamylated haemoglobin are still critical points for HbA1c measurement

“…HbA 1c is also an important predictive marker of long term complications of diabetes ( 4 , 5 ). HbA 1c assays can be performed using different analytical principles including separative methods such as high performance liquid chromatography (HPLC) and capillary electrophoresis, but also immunological and enzymatic methods.…”

Alterations in mitochondrial functions and morphology in muscle and non‐muscle tissues in type 1 diabetes: implications for metabolic health

“…We acknowledge that many factors are at play in determining the PCr/ATP equilibrium, including rates of mitochondrial oxidative phosphorylation, microvascular dysfunction and the presence of cardiac fibrosis. The latter refers to the fact that people with T1D are known to have increased myocardial fibrosis (Armstrong et al., ), an observation that would imply that their cardiomyocytes have to work at a higher workload per cell to compensate for the smaller LV volume fraction. This would not only lead to an inability in maintaining the PCr/ATP ratio, but also a lower maximal cardiac output and .…”